ResMed Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ResMed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.
View analyst ratings for ResMed or view top-rated stocks.

Wall Street analysts have given ResMed a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ResMed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ResMed saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 1,230,000 shares, an increase of 16.0% from the July 29th total of 1,060,000 shares. Based on an average daily trading volume, of 560,300 shares, the days-to-cover ratio is currently 2.2 days. Approximately 0.9% of the company's shares are short sold.
View ResMed's Short Interest.

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for ResMed.

ResMed Inc. (NYSE:RMD) announced its earnings results on Thursday, August, 5th. The medical equipment provider reported $1.35 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.25 by $0.10. The medical equipment provider earned $876.10 million during the quarter, compared to analysts' expectations of $781.10 million. ResMed had a net margin of 14.84% and a trailing twelve-month return on equity of 28.03%. During the same period last year, the company earned $1.33 earnings per share.
View ResMed's earnings history.

ResMed's stock was trading at $153.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RMD shares have increased by 86.2% and is now trading at $285.95.
View which stocks have been most impacted by COVID-19.

ResMed announced a quarterly dividend on Thursday, August 5th. Stockholders of record on Thursday, August 19th will be paid a dividend of $0.42 per share on Thursday, September 23rd. This represents a $1.68 annualized dividend and a yield of 0.59%. The ex-dividend date is Wednesday, August 18th. This is a boost from ResMed's previous quarterly dividend of $0.39.
View ResMed's dividend history.

ResMed pays an annual dividend of $1.68 per share and currently has a dividend yield of 0.59%. The dividend payout ratio of ResMed is 31.52%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ResMed will have a dividend payout ratio of 25.19% next year. This indicates that ResMed will be able to sustain or increase its dividend.
View ResMed's dividend history.

12 equities research analysts have issued twelve-month target prices for ResMed's shares. Their forecasts range from $210.00 to $270.00. On average, they anticipate ResMed's share price to reach $241.50 in the next year. This suggests that the stock has a possible downside of 15.5%.
View analysts' price targets for ResMed or view top-rated stocks among Wall Street analysts.

284 employees have rated ResMed CEO Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among ResMed's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to ResMed include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), STERIS (STE), Insulet (PODD), Hologic (HOLX), Teleflex (TFX) and Abiomed (ABMD).
View all of RMD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), The Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.59%), BlackRock Inc. (8.70%), WCM Investment Management LLC (6.26%), State Street Corp (4.26%), FMR LLC (2.89%) and Baillie Gifford & Co. (2.23%). Company insiders that own ResMed stock include Brett Sandercock, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed.

RMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Los Angeles Capital Management LLC, JPMorgan Chase & Co., CIBC Asset Management Inc, Prudential Financial Inc., Nuveen Asset Management LLC, and Bank of America Corp DE. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Rajwant Sodhi, Robert Andrew Douglas, and Ronald R Taylor.
View insider buying and selling activity for ResMed or view top insider-selling stocks.

RMD stock was purchased by a variety of institutional investors in the last quarter, including Amundi, Ownership Capital B.V., Geode Capital Management LLC, Alyeska Investment Group L.P., Morgan Stanley, Morgan Stanley, Baillie Gifford & Co., and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for ResMed or or view top insider-buying stocks.

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RMD stock can currently be purchased for approximately $285.95.

ResMed has a market capitalization of $41.66 billion and generates $3.20 billion in revenue each year. The medical equipment provider earns $474.51 million in net income (profit) each year or $5.33 on an earnings per share basis.

ResMed employs 7,970 workers across the globe.

ResMed was founded in 1989.

The official website for ResMed is www.resmed.com.

ResMed is headquartered at 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123.

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at (858) 836-5000 or via email at [email protected].